Page 8 - Hoag Neurosciences Institute Annual Report
P. 8






stRoKe PRogRAM




support & education

A Stroke Support group meets monthly in the Hoag 
Conference Center. There is an education presentation David Brown: Antihypertensive Treatment of Acute Cerebral 
Hemorrhage (ATACH)-II: A Phase III Randomized Multicenter 
along with Q&A facilitated by the Stroke Nurse Clinical Trial of Blood Pressure Reduction for Hypertension 
Navigator. The meeting is attended by Stroke survivors in Acute Intracerebral Hemorrhage. National Institute

and their friends & family members.
of Neurological Disorders and Stroke (NINDS), Bethesda, 
Maryland, United States 20110757.
A Brain Aneurysm & AVM support group meets

every other month in the Hoag Conference Center. William Cloud (ER) and David Brown: THE FIELD 
There is an education presentation along with Q&A ADMINISTRATION OF STROKE THERAPY – MAGNESIUM 
(FAST- MAG) PHASE 3 CLINICAL TRIAL. Multicenter, 
facilitated by the Stroke Nurse Navigator. The meeting randomized, placebo-controlled, double-blind, parallel group 

is attended by survivors and their family and friends.
trial of intravenous magnesium sulfate initiated by paramedics 
in the field within 2 hours of symptom onset in 1700 patients 
Community Outreach is provided through education with acute stroke. UO1 NS044364 National Institute of 
presentations by Dr. Brown and Deb Mastrolia at both Neurologic Disorders and Stroke - National Institute of Health.

Hoag Hospital Newport Beach and Hoag Irvine. They 
teach the signs and symptoms of a stroke, stroke David Brown: NeuroThera Effectiveness and Safety Trial –
3 (NEST-3). A double-blind, randomized, sham-controlled, 
prevention and treatments. Community Medicine, 
parallel group, muliticenter, pivotal study to assess the safety 
along with the help of Dr. Parry, has supported the and efficacy of transcranial laser therapy with the NeuroThera® 
stroke program with thousands of tools to help teach Laser System for the treatment of acute ischemic stroke with 
within 24 hours of stroke onset.
stroke recognition to the public, including FAST 
magnets and FAST jar openers. The stroke program 
David Brown: ICTuS2/3 Intravenous Thrombolysis
also attends employee health fairs, senior centers and and Hypothermia for Acute Treatment of Ischemic Stroke. 
events, and performs blood pressure checks, while 
NIH Funded.
reviewing stroke risks and prevention.
David Brown: Interventional Management of Stroke (IMS III):
A Phase 3, Randomized, Multi-Center, Open Label, 900 Subject 
Clinical Research
Clinical Trial that will examine whether a combined intravenous 
(IV) and intra-arterial (IA) approach to recanalization is superior 
David Brown: Acorda DALF-PS-1003: A Phase 1b Study
to standard IV rt-PA (Activase®) alone when initiated within three 
of Dalfampridine 10 mg Extended Release Tablet in Subjects 
with Chronic Deficits After Ischemic Stroke.
hours of acute ischemic stroke onset. NIH Funded.

Wallace Peck (IR): Penumbra CLP 4853.A: A randomized, 
David Brown: ASBI 801 Study- A Muliticenter Observational concurrent controlled trial to assess the safety and effectiveness 
Study to Evaluate the Simplified-Stroke Rehabilitation 
Assessment of Movement (S-STREAM) Scale in Subjects of the Separator 3D as a component of the Penumbra System 
in the revascularization of large vessel occlusion in acute 
Obtained Between 24 and 48 Hours of a Nonhemorrhagic ischemic stroke.
Ischemic Stroke.

David Brown: GEN-002 A Phase 2, Double-Blind, Placebo- Michael Brant-Zawadzki: Penumbra, Inc: ACE “An Aneurysm 
Coiling Efficiency Study of the Penumbra Coil 400 System”.
Controlled Dose Escalation Study to Evaluate the Efficacy 
and Safety of GM602 in Patients with Acute Middle Cerebral 
Artery Ischemic Stroke Within an 18-Hour treatment Window. 

Genervon Biopharmaceuicals, LLC.























6



   6   7   8   9   10